ReviewFrontiers in genetics2025
Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors.
Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
- Exploring the Impact of Nanotherapeutics on Histone H3 and H4 Acetylation Enrichment in Cancer Epigenome: A Systematic Scoping Synthesis.Epigenomes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer vaccines represent a promising therapeutic modality in immuno-oncology, yet their efficacy is severely constrained within the immunosuppressive microenvironment of lung tumors. Metabolic reprogramming and epigenetic dysregulation are now understood as critical, interconnected determinants that orchestrate tumor microenvironment (TME) immunosuppression and fundamentally shape anti-tumor immune responses. This review comprehensively examines the mechanistic interplay between metabolic reprogramming and epigenetic regulation, and how nanoplatform technologies can be engineered to modulate these axes to augment cancer vaccine efficacy. We analyze advanced nano-delivery system design strategies, the synergistic effects of combining metabolic intervention with epigenetic modification, and their application in overcoming the formidable barriers of the lung TME. By integrating recent advances in nanotechnology, epigenetics, and tumor immunometabolism, we provide critical insights into the development of next-generation cancer vaccines. Furthermore, we propose a novel conceptual framework-The Epi-Met-Immune Synergistic Network-to dissect these interactions and identify key nodes for rational therapeutic intervention, aiming to enhance and sustain durable anti-tumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.